SCD-Haplo: A Phase II Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease
Phase of Trial: Phase II
Latest Information Update: 03 Sep 2019
Price : $35 *
At a glance
- Drugs Alemtuzumab (Primary) ; Cyclophosphamide; Sirolimus
- Indications Sickle cell anaemia; Transplant rejection
- Focus Therapeutic Use
- Acronyms SCD-Haplo
- 22 Aug 2019 Status changed from active, no longer recruiting to discontinued.
- 24 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 27 Jan 2014 New trial record